Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
      • ECFS Intestinal Organoid Working Group
      • Intestinal Organoid Working Group
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

CFTR modulators

What is the best approach to bring drugs to all people with CF?

  • Read more about What is the best approach to bring drugs to all people with CF?

Differences between the United States and the European Union in the time of approval of CFTR modulators for the treatment of cystic fibrosis

  • Read more about Differences between the United States and the European Union in the time of approval of CFTR modulators for the treatment of cystic fibrosis

Correlation between trough concentration and exposure during the day for elexacaftor, tezacaftor and ivacaftor

  • Read more about Correlation between trough concentration and exposure during the day for elexacaftor, tezacaftor and ivacaftor

CFTR modulators in people with CF and the I1234V mutation

  • Read more about CFTR modulators in people with CF and the I1234V mutation

Amount of chloride in the sweat of people with CF taking CFTR modulators

  • Read more about Amount of chloride in the sweat of people with CF taking CFTR modulators

Use of CFTR modulators in patients having undergone liver transplantation

  • Read more about Use of CFTR modulators in patients having undergone liver transplantation

Changes in cholesterol levels in people with cystic fibrosis after starting highly effective modulators

  • Read more about Changes in cholesterol levels in people with cystic fibrosis after starting highly effective modulators

Changes in pancreatic enzyme function for children with cystic fibrosis while taking modulators (Trikafta®, Orkambi®, Symdeco®, and Kalydeco®)

  • Read more about Changes in pancreatic enzyme function for children with cystic fibrosis while taking modulators (Trikafta®, Orkambi®, Symdeco®, and Kalydeco®)

CFTR modulator therapy may improve lipid levels in children and adolescents with cystic fibrosis.

  • Read more about CFTR modulator therapy may improve lipid levels in children and adolescents with cystic fibrosis.

Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis

  • Read more about Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis
  • first
  • previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2026. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)